Skip to main content
  • Robocath receives NMPA approval for R-One robotic platform in China

    Rouen, France, January 9, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular diseases, today announces the granting of a marketing authorization to distribute its R-One robotic platform in China. This was issued on December 8, by the Chinese National Medical Products Administration (NMPA); making it the first vascular robotic platform to be granted approval in China.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details